Center for Sleep Medicine, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
Department of Neurology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
J Clin Sleep Med. 2023 Apr 1;19(4):741-748. doi: 10.5664/jcsm.10436.
The development of restless legs syndrome (RLS) has been rarely reported during and following opioid withdrawal. We aimed to determine the presence and severity of RLS symptoms during and after supervised opioid tapering.
Ninety-seven adults enrolled in the Mayo Clinic Pain Rehabilitation Center who underwent supervised prescription opioid tapering were prospectively recruited. RLS presence and severity was assessed with the Cambridge-Hopkins Questionnaire 13 and International Restless Legs Syndrome Study Group Rating Severity Scale at admission, midpoint, and dismissal from the program as well as 2 weeks, 4 weeks, and 3 months after completion. Frequency and severity of RLS symptoms were compared between admission and each time point.
Average age of the cohort was 52.6 ± 13.3 years with a morphine milligram equivalent dose for the cohort of 45.6 ± 48.3 mg. Frequency of RLS symptoms increased from 28% at admission to peak frequency of 41% at 2 weeks following discharge from the Mayo Pain Rehabilitation Clinic ( = .01), returning to near baseline frequency 3 months after opioid discontinuation. International Restless Legs Syndrome Study Group Rating Severity Scale increased from baseline and then remained relatively stable at each time point following admission. Thirty-five (36.1%) participants developed de novo symptoms of RLS during their opioid taper, with those being exposed to higher morphine milligram equivalent doses having higher risk of developing RLS.
Moderately severe symptoms of RLS, as assessed by survey, occur commonly in individuals undergoing opioid tapering, particularly if exposed to higher doses. In many cases, symptoms appear to be self-limited, although a minority develop persistent symptoms. Our results may have implications for successful opioid tapering, but future confirmatory studies with structured clinician interview are needed to establish that these symptoms truly represent restless legs syndrome given the potential for RLS-mimicking symptoms in individuals with chronic pain syndromes.
McCarter SJ, Labott JR, Mazumder MK, et al. Emergence of restless legs syndrome during opioid discontinuation. . 2023;19(4):741-748.
在阿片类药物戒断期间和之后,不安腿综合征(RLS)的发展很少有报道。我们旨在确定在监督下进行阿片类药物逐渐减量期间和之后 RLS 症状的存在和严重程度。
97 名在梅奥诊所疼痛康复中心接受监督处方阿片类药物逐渐减量的成年人被前瞻性招募。在入院时、中点时、从项目中出院时以及出院后 2 周、4 周和 3 个月,使用剑桥-霍普金斯问卷 13 和国际不安腿综合征研究组严重程度量表评估 RLS 症状的存在和严重程度。比较入院时和每个时间点 RLS 症状的频率和严重程度。
队列的平均年龄为 52.6±13.3 岁,队列的吗啡毫克当量剂量为 45.6±48.3mg。RLS 症状的频率从入院时的 28%增加到出院后 2 周时的峰值 41%(=0.01),在停用阿片类药物 3 个月后恢复到接近基线频率。国际不安腿综合征研究组严重程度量表从基线开始增加,然后在入院后每个时间点保持相对稳定。35 名(36.1%)参与者在阿片类药物逐渐减量期间出现新的不安腿综合征症状,暴露于较高吗啡毫克当量剂量的参与者发生 RLS 的风险更高。
根据调查评估,中度严重的 RLS 症状在接受阿片类药物逐渐减量的个体中很常见,尤其是如果暴露于较高剂量的情况下。在许多情况下,症状似乎是自限性的,尽管少数人出现持续性症状。我们的结果可能对成功进行阿片类药物逐渐减量有影响,但需要进一步进行有结构的临床医生访谈的前瞻性研究,以确定这些症状是否真正代表不安腿综合征,因为慢性疼痛综合征患者可能会出现 RLS 样症状。
McCarter SJ, Labott JR, Mazumder MK, et al. 在阿片类药物戒断期间出现不安腿综合征。. 2023;19(4):741-748.